IJERPH, Vol. 17, Pages 3603: Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab
Conclusions: Intraperitoneal chemotherapy seems to be superior in progression free survival and overall survival to dose-dense chemotherapy in the frontline treatment of women with optimally resected advanced ovarian, fallopian tube or primary peritoneal cancer and not receiving bevacizumab.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Ting Hsiao Chen Wei Lin Hsiao Tags: Article Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Environmental Health | Fallopian Tube Cancer | International Medicine & Public Health | Ovarian Cancer | Ovaries | Peritoneal Cancer | Women